HeartBeam Stock Soars 38% on FDA Clearance and New 24/7 Cardiology Partnership

Introduction

HeartBeam, Inc. (NASDAQ: BEAT) is a Santa Clara, California–based medical technology company specializing in at-home cardiac monitoring. Its flagship product, the HeartBeam AIMIGo™, is a credit-card-sized, cable-free device that collects three-dimensional ECG signals and synthesizes them into a 12-lead ECG. The company’s platform is designed to assist physicians in detecting arrhythmias and acute cardiac events outside of traditional clinical settings.

Corporate Structure

Founded in 2015, HeartBeam maintains its headquarters at 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050. The company employs between 11 and 50 individuals in various roles including research and development, regulatory affairs, manufacturing, and corporate functions. HeartBeam holds over 20 issued patents and is classified under Healthcare Providers & Services (NAICS 923120; SIC 5045).

Cardiac Monitoring by Jair Lázaro

Developments and News

• December 2024: The U.S. Food and Drug Administration granted clearance for HeartBeam’s 3D ECG technology for arrhythmia assessment.
• August 13, 2025: Filing of the 10-Q quarterly report for the period ended June 30, 2025 (Acc-no: 0001628280-25-040135).
• November 13, 2025: Filing of the 10-Q quarterly report for the period ended September 30, 2025 (Acc-no: 0001193125-25-280112).
• November 13, 2025: Conducted the Q3 2025 earnings call, led by CEO Rob Eno and CFO Timothy Cruickshank, discussing regulatory initiatives and commercial-readiness milestones.
• November 21, 2025: Filed Form 8-K reporting material corporate events (Acc-no: 0001213900-25-113353).
• Coverage Initiation: ROTH Capital Partners initiated coverage of BEAT with a Buy rating and a $4.00 price target, focusing on anticipated FDA clearance for its 12-lead ECG synthesis software.
• Strategic Alliance: HeartBeam announced a partnership with HeartNexus to provide on-demand, 24/7 cardiologist review through its at-home monitoring platform.
• Intellectual Property Recognition: A PatentVest report ranked HeartBeam second among 243 companies for innovation in 12-lead ECG technology, highlighting 82 global patent publications across 15 patent families.

Financial and Strategic Analysis

HeartBeam shares closed at $0.8316 on November 28, 2025, reflecting a 37.75% increase on a volume of 14,631,977 shares traded on the NASDAQ exchange. The 10-Q filings dated November 13 and August 13, 2025, provide general narratives on revenue trends, cash flow, and risk factors, but specific financial metrics were not disclosed. Key strategic drivers include:

• FDA clearance for arrhythmia assessment, positioning the AIMIGo device for physician-directed care pathways.
• Ongoing FDA review of the 12-lead ECG synthesis software, which may support broader commercial adoption.
• A patent portfolio exceeding 20 issued patents, which supports differentiation in the portable ECG market.
• Partnerships, such as the HeartNexus collaboration, which may expand service offerings and enhance revenue generation through remote cardiology reading services.

Market Position and Industry Context

HeartBeam operates in the remote cardiac monitoring segment, part of the broader digital health and medical equipment manufacturing industries. The increased focus on telehealth and decentralized care models has driven demand for portable, clinical-grade ECG devices. Competitors include established medical device firms such as GE HealthCare, which leads in patent output; however, HeartBeam’s vector-based, cable-free approach aims to address limitations in symptom-triggered ECG capture. The integration of compact hardware and actionable heart intelligence distinguishes HeartBeam in the field of patient-centric cardiac diagnostics.

TL;DR

HeartBeam’s stock (NASDAQ: BEAT) rose 37.75% to $0.8316 on November 28, 2025, with trading volume at 14.6 million shares. The company holds FDA clearance for its 3D arrhythmia assessment device and is awaiting FDA approval of its 12-lead ECG synthesis software. Recent SEC filings (10-Q and 8-K) reflect operational updates but do not include detailed financial figures. Strategic actions include ROTH coverage with a $4 price target, a partnership with HeartNexus for 24/7 cardiology review, and recognition by PatentVest for ECG innovation. Upcoming milestones are dependent on software clearance and the commercial rollout of physician-directed remote monitoring.